Aardvark Therapeutics, Inc.
AARD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001774857
In the last 90 days, Aardvark Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $54.3M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Aardvark Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 79 | 2 | 71 | −6 |
| Shares | 10.2M | 6.04K | 9.43M | −762.8K (−7.5%) |
| Value | $38.5M | $22.8K | $54.3M | +$15.9M (+41.4%) |
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Aardvark Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| EcoR1 Capital, LLC | 396,194 | $2.28M | 0.11% |
| J. Goldman & Co LP | 40,500 | $233.3K | 0.01% |
| Susquehanna International Group, LLP | 24,025 | $138.4K | 0.00% |
| Point72 Asset Management, L.P. | 22,872 | $131.7K | 0.00% |
| Jane Street Group, LLC | 22,464 | $129.4K | 0.00% |
| Mariner, LLC | 21,784 | $125.4K | 0.00% |
| Smith, Moore & Co. | 20,000 | $115.2K | 0.01% |
| Marshall Wace, LLP | 19,076 | $109.9K | 0.00% |
| Wealth Enhancement Advisory Services, LLC | 10,434 | $79.3K | 0.00% |
| Mercer Global Advisors Inc | 11,464 | $66.0K | 0.00% |
| Cerity Partners LLC | 10,771 | $62.0K | 0.00% |
| Abel Hall, LLC | 10,066 | $58.0K | 0.01% |
| GAMMA Investing LLC | 388 | $2.23K | 0.00% |
| Nisa Investment Advisors, LLC | 70 | $403 | 0.00% |
| Fortitude Family Office, LLC | 56 | $323 | 0.00% |
| Wealth Enhancement Trust Services, Inc. | 48 | $276 | 0.00% |
| Clearstead Advisors, LLC | 39 | $226 | 0.00% |
| JPL Wealth Management, LLC | 7 | $41 | 0.00% |
Sold out (24)
Institutions that held Aardvark Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
Not filed for Q2 2026 yet (2)
Institutions that held Aardvark Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| CWM, LLC | 6,035 | $22.8K |
| Sunbelt Securities, Inc. | 4 | $15 |